| Immune mechanisms involved in cardiovascular complications of chronic kidney disease. | |
| | |
MedLine Citation:
|
PMID: 20093815 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
A sustained status of chronic inflammation is closely linked to several complications of chronic kidney disease (CKD), such as vascular degeneration, myocardial fibrosis, loss of appetite, insulin resistance, increased muscle catabolism and anemia. These consequences of a chronically activated immune system impact on the acceleration of atherosclerosis, vascular calcification and development of heart dysfunction. Recent evidence suggests that these immune-mediated consequences of uremic toxicity are not only important to stratify the risk and understand the mechanisms of disease, but also represent an important area for intervention. Thus, the aim of this brief review is to discuss the immune mechanisms behind atherosclerosis and myocardiopathy in CKD. We also display the emerging evidence that strategies focusing on modulating the immune response or reducing the generation of triggers of inflammation may represent an important tool to reduce mortality in this group of patients. Ongoing studies may generate the evidence that will translate these strategies to definitive changes in clinical practice. |
| | |
Authors:
|
Andr?a E M Stinghen; Sergio Bucharles; Miguel C Riella; R Pecoits-Filho |
Related Documents
:
|
11712755 - The molecular and cellular pathology of inflammatory muscle diseases. 15207815 - Pdgf and cardiovascular disease. 17553935 - Xenogenic macrophage immunization reduces atherosclerosis in apolipoprotein e knockout ... 18465575 - Role of chemokines in atherosclerosis. 17135575 - Prostaglandin i2 analogs inhibit th1 and th2 effector cytokine production by cd4 t cells. 21674475 - Il-9 is important for t cell activation and differentiation in autoimmune inflammation ... |
Publication Detail:
|
Type: Journal Article; Review Date: 2010-01-08 |
Journal Detail:
|
Title: Blood purification Volume: 29 ISSN: 1421-9735 ISO Abbreviation: Blood Purif. Publication Date: 2010 |
Date Detail:
|
Created Date: 2010-01-22 Completed Date: 2010-04-29 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8402040 Medline TA: Blood Purif Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 114-20 Citation Subset: IM |
Copyright Information:
|
Copyright (c) 2010 S. Karger AG, Basel. |
Affiliation:
|
Center for Health and Biological Sciences, Pontif?cia Universidade Cat?lica do Paran?, Curitiba, Brazil. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Angiotensin II Type 1 Receptor Blockers
/
therapeutic use Angiotensin-Converting Enzyme Inhibitors / therapeutic use Animals Anti-Inflammatory Agents / therapeutic use Antihypertensive Agents / therapeutic use Antioxidants / therapeutic use Atherosclerosis / etiology, immunology, prevention & control Cardiomyopathies / etiology, immunology, prevention & control Cardiovascular Diseases / etiology*, immunology, prevention & control Chronic Disease Clinical Trials as Topic Endothelium, Vascular / physiopathology Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use Inflammation / drug therapy, etiology, immunology Interleukin-6 / secretion Kidney Diseases / complications*, immunology, therapy Membranes, Artificial Mice Periodontitis / complications Renal Dialysis / adverse effects Tumor Necrosis Factor-alpha / secretion Vasculitis / etiology, immunology, physiopathology |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Anti-Inflammatory Agents; 0/Antihypertensive Agents; 0/Antioxidants; 0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/IL6 protein, human; 0/Interleukin-6; 0/Membranes, Artificial; 0/Tumor Necrosis Factor-alpha |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Aldosterone in Uremia - Beyond Blood Pressure.
Next Document: An Approach to Addressing Depression in Patients with Chronic Kidney Disease.